Trillium Therapeutics Inc (TRIL)

[NY1972]

Comment from Biomaven:

http://www.siliconinvestor.com/readmsg.aspx?msgid=31056707

>>1 MRD+ AML pts achieved complete molecular remission quickly after
4 weekly TTI-621 infusions and remain in ongoing remission for 15+ weeks. This pts was refractory/relapse (r/r) from multiple prior therapies including allogeneic HSCT, which usually suggests poor prognosis. This pts is the only MRD+ AML pts treated, thus 1/1 r/r MRD+ AML pts achieved CMR so far after TTI-621 treatment.

Also, 3/6 lymphoma pts achieved and remain in ongoing PMR with tumor shrinkage for 19+ (DLBCL), 18+ (transformed lymphoma), and 8+ weeks (follicular lymphoma) with weekly infusion of TTI-621 and Rituxan. The PMR are determined by Lugano 2014 criteria (Exhibit 1), which recommends using PET-CT metabolic uptake and the 5-point scale as the standard response criteria for FDG-avid lymphoma (e.g. DLBCL, HL, FL) rather than CT scan-based tumor size change, as PET-CT is shown to be more accurate and prognostic for outcome than CT for FDG-avid lymphoma (Cheson BD et al. J Clin Oncol. 2014). A PMR at interim analysis using the Lugano 2014 criteria indicates responding pts (Exhibit 1). Thus, 3/6 lymphoma pts responded to TTI-621 + Rituxan. Note that these pts have been r/r from multiple prior therapies and all pts were r/r from prior Rituxan treatments.<<